S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
NASDAQ:GERN

Geron Stock Forecast, Price & News

$1.45
+0.01 (+0.69%)
(As of 12/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.41
$1.47
50-Day Range
$1.32
$1.72
52-Week Range
$1.20
$2.36
Volume
1.27 million shs
Average Volume
4.17 million shs
Market Capitalization
$466.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.08
30 days | 90 days | 365 days | Advanced Chart
Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter.


Geron logo

About Geron

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:GERN
CUSIP
37416310
Employees
54
Year Founded
N/A

Sales & Book Value

Annual Sales
$250 thousand
Book Value
$0.47 per share

Profitability

Net Income
$-75.62 million
Net Margins
-26,769.73%
Pretax Margin
-26,769.72%

Debt

Price-To-Earnings

Miscellaneous

Free Float
302,954,000
Market Cap
$466.83 million
Optionable
Optionable

Company Calendar

Last Earnings
11/09/2021
Today
12/09/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/10/2022

MarketRank

Overall MarketRank

1.80 out of 5 stars

Medical Sector

843rd out of 1,394 stocks

Pharmaceutical Preparations Industry

406th out of 674 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












Geron (NASDAQ:GERN) Frequently Asked Questions

Is Geron a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Geron stock.
View analyst ratings for Geron
or view top-rated stocks.

How has Geron's stock price been impacted by Coronavirus?

Geron's stock was trading at $1.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GERN stock has increased by 40.8% and is now trading at $1.45.
View which stocks have been most impacted by COVID-19
.

When is Geron's next earnings date?

Geron is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Geron
.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) released its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. The biopharmaceutical company earned $0.11 million during the quarter, compared to the consensus estimate of $0.10 million. Geron had a negative net margin of 26,769.73% and a negative trailing twelve-month return on equity of 58.33%.
View Geron's earnings history
.

What price target have analysts set for GERN?

4 equities research analysts have issued twelve-month price targets for Geron's stock. Their forecasts range from $4.00 to $7.00. On average, they expect Geron's share price to reach $5.50 in the next year. This suggests a possible upside of 279.3% from the stock's current price.
View analysts' price targets for Geron
or view top-rated stocks among Wall Street analysts.

Who are Geron's key executives?

Geron's management team includes the following people:
  • John A. Scarlett, Chairman, President & Chief Executive Officer
  • Andrew J. Grethlein, Chief Operating Officer & Executive Vice President
  • Olivia K. Bloom, Chief Financial Officer, Treasurer & Executive VP
  • Aleksandra Rizo, Chief Medical Officer & Executive Vice President
  • Stephen N. Rosenfield, Secretary, Chief Legal Officer & Executive VP

What is John A. Scarlett's approval rating as Geron's CEO?

5 employees have rated Geron CEO John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among Geron's employees.

What other stocks do shareholders of Geron own?

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

Who are Geron's major shareholders?

Geron's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.96%), BioImpact Capital LLC (1.78%), Geode Capital Management LLC (1.74%), Millennium Management LLC (0.44%), Bank of New York Mellon Corp (0.35%) and Alliancebernstein L.P. (0.20%).
View institutional ownership trends for Geron
.

Which major investors are selling Geron stock?

GERN stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Morgan Stanley, Citadel Advisors LLC, Cubist Systematic Strategies LLC, New York State Common Retirement Fund, California State Teachers Retirement System, Rafferty Asset Management LLC, and Squarepoint Ops LLC.
View insider buying and selling activity for Geron
or view top insider-selling stocks.

Which major investors are buying Geron stock?

GERN stock was bought by a variety of institutional investors in the last quarter, including BioImpact Capital LLC, Millennium Management LLC, Geode Capital Management LLC, UBS Group AG, Goldman Sachs Group Inc., BlackRock Inc., SG Americas Securities LLC, and Nisa Investment Advisors LLC.
View insider buying and selling activity for Geron
or or view top insider-buying stocks.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $1.45.

How much money does Geron make?

Geron has a market capitalization of $466.83 million and generates $250 thousand in revenue each year. The biopharmaceutical company earns $-75.62 million in net income (profit) each year or ($0.33) on an earnings per share basis.

How many employees does Geron have?

Geron employs 54 workers across the globe.

What is Geron's official website?

The official website for Geron is www.geron.com.

Where are Geron's headquarters?

How can I contact Geron?

Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at (650) 473-7700, via email at [email protected], or via fax at 650-473-7750.


This page was last updated on 12/9/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.